The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $5.53

Today's change+0.03 +0.55%
Updated February 12 4:00 PM -5GMT. Delayed by at least 15 minutes.
 

Merrimack Pharmaceuticals Inc

Nasdaq: MACK
Last

(U.S.) $5.53

Today's change+0.03 +0.55%
Updated February 12 4:00 PM -5GMT. Delayed by at least 15 minutes.

Merrimack Pharmaceuticals Inc up (U.S.)$0.03

Merrimack Pharmaceuticals Inc closed up Friday by (U.S.)$0.03 or 0.55% to (U.S.)$5.53. Over the last five days, shares have lost 8.44% and are down 30.00% for the last year to date. This security has underperformed the S&P 500 by 33.00% during the last year.

Key company metrics

  • Open(U.S.) $5.61
  • Previous close(U.S.) $5.50
  • High(U.S.) $5.64
  • Low(U.S.) $5.17
  • Bid / Ask-- / --
  • YTD % change-30.00%
  • Volume1,657,307
  • Average volume (10-day)1,768,899
  • Average volume (1-month)1,620,559
  • Average volume (3-month)1,484,743
  • 52-week range(U.S.) $5.10 to (U.S.) $13.84
  • Beta1.54
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.00
Updated February 12 4:00 PM -5GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-107.32%

Although this company's net profit margin is negative, it is above the industry average and implies that Merrimack Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX2.43%Sector:HealthcareIndustry:Biotechnology

Latest Company News

    No News Results.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue16371534
Total other revenue--------
Total revenue16371534
Gross profit--------
Total cost of revenue--------
Total operating expense55554539
Selling / general / administrative171298
Research & development38433631
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-38-19-30-5
Interest income (expense), net non-operating-4-4-5-5
Gain (loss) on sale of assets--------
Other--------
Income before tax-42-23-34-9
Income after tax-42-23-34-9
Income tax, total--------
Net income-43-23-35-10
Total adjustments to net income--------
Net income before extra. items-43-23-35-10
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-43-23-35-10
Inc. avail. to common incl. extra. items-43-23-35-10
Diluted net income-43-23-35-10
Dilution adjustment--------
Diluted weighted average shares112110107106
Diluted EPS excluding extraordinary itemsvalue per share-0.38-0.21-0.32-0.09
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.38-0.21-0.32-0.09